RT Journal Article SR Electronic T1 Strategies to examine new compounds for intraperitoneal use in ovarian cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 33 OP 35 DO 10.1111/j.1525-1438.2007.01102.x VO 18 IS Suppl 1 A1 M. Markman YR 2008 UL http://ijgc.bmj.com/content/18/Suppl_1/33.abstract AB The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena